Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829716 | 0.82 | KDM4E (0.51) | LMNAMAPTALDH1A1MAPK1MEN1 | |
| SCHEMBL4832008 | 0.80 | TDP1 (0.48) | LMNAMAPTALDH1A1MAPK1MEN1 | |
| SCHEMBL3838071 | 0.79 | LOXL2 (0.54) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2742576 | 0.79 | ALDH1A1 (0.62) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL9827937 | 0.78 | KMT2A (0.58) | LMNAMAPTALDH1A1MAPK1MEN1 | |
| SCHEMBL5065594 | 0.76 | CYP1A2 (0.50) | LMNAMAPTALDH1A1SMN1; SMN2HTT | |
| SCHEMBL2673969 | 0.76 | LOXL2 (0.59) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL3796739 | 0.76 | AKR1C3 (0.55) | MAPTALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL16189625 | 0.74 | SMN1; SMN2 (0.66) | LMNAMAPTALDH1A1MAPK1MEN1 | |
| Hydrochloric Acid SCHEMBL11771000 | 0.74 | IDO1 (0.57) | LMNAMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | LMNA 3037/4885MAPT 3605/4885ALDH1A1 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.